Needham analyst Joseph Stringer has maintained their bullish stance on PCVX stock, giving a Buy rating on April 1.
Joseph Stringer has given his Buy rating due to a combination of factors that highlight Vaxcyte’s promising prospects. The company’s recent data from the VAX-24 Phase 2 infant study has shown encouraging results, which bolster confidence in its potential success. Additionally, the expectations surrounding the VAX-31 Phase 2 infant program are positive, suggesting further advancements in their vaccine development pipeline.
Moreover, the introduction of the VAX-XL program indicates Vaxcyte’s commitment to expanding its product offerings, which could enhance its market position. The discussions with Vaxcyte’s leadership at the Needham Healthcare Conference have provided insights into the company’s strategic direction and growth potential, reinforcing the Buy rating. Overall, these elements combined suggest a favorable outlook for Vaxcyte’s stock performance.
In another report released on April 1, Goldman Sachs also maintained a Buy rating on the stock with a $100.00 price target.